Episode Player

Send us Fan Mail

Learn more at CMTsummit.org

Your laptop can give you a thousand links about Charcot-Marie-Tooth disease, but it can’t give you certainty, context, or a hand on your shoulder when the fear spikes at 2 a.m. We dig into the newly released agenda for the HF Clinical Trial Readiness Summit Plus Retreat (April 16–18, 2026 in Ellicott City, Maryland) to answer a blunt question: why show up in person when the internet is overflowing with medical information? 

We walk through the rare disease clinical trial problem set that keeps CMT therapies slow and scarce: small patient populations, highly variable symptoms, rigid legacy trial designs, and the need for FDA-ready endpoints. From new regulatory thinking to the push for a unified CMT data ecosystem, we explain what “trial readiness” really means and why it’s more than slides and jargon. We also unpack how biobanks and wearable studies turn real life into usable evidence by capturing continuous gait and fatigue signals that a short clinic visit will never see. 

Then we shift to the parts of living with CMT that research often misses: breathing, hearing, eyesight, sleep, and the exhausting reality of fatigue. You’ll hear why a new validated CMT fatigue assessment matters for drug approval, and why practical sessions, respiratory tools, and hands-on demos like bracing, orthotics, adaptive driving, service dogs, and everyday gadgets can replace abstract anxiety with tactile clarity. Finally, we make the case that the most powerful “intervention” might be community itself, because isolation has measurable physical costs and connection can change the baseline. 

If this resonates, subscribe, share this with someone navigating CMT, and leave a review so more people can find the conversation. What’s the one tool, symptom, or question you wish researchers would take more seriously?

Thanks for listening! Learn more at hnf-cure.org and subscribe for more updates on CMT research and advancements.